What is BioEclipse Therapeutics?
BioEclipse Therapeutics is a clinical-stage biopharmaceutical company dedicated to pioneering novel immunotherapies for advanced cancer patients who have limited treatment alternatives. The company's core innovation lies in its proprietary allogeneic technology, engineered to activate both innate and adaptive immune responses to combat solid tumors, which represent the vast majority of cancer diagnoses. With promising therapeutic candidates such as CRX200 and CRX100, BioEclipse aims to deliver cost-effective, engineered immune solutions with demonstrated potency against a spectrum of tumor types. Their strategic objective is to achieve complete disease eradication and establish durable, tumor-specific immunity in individuals battling resistant and recurrent solid tumors.
How much funding has BioEclipse Therapeutics raised?
BioEclipse Therapeutics has raised a total of $7.7M across 1 funding round:
Other Financing Round
$7.7M
Other Financing Round (2019): $7.7M with participation from Revelis Capital Group , LLC
Key Investors in BioEclipse Therapeutics
Revelis Capital Group , LLC
Revelis Capital Group, LLC is an investment firm that has participated in BioEclipse Therapeutics' funding rounds. Further details on their specific investment focus are not publicly available.
What's next for BioEclipse Therapeutics?
The substantial enterprise-level backing positions BioEclipse Therapeutics for accelerated development and potential commercialization of its innovative cancer therapies. This strategic investment is expected to fuel further clinical trials, enhance manufacturing capabilities, and expand the company's research and development pipeline. The company's focus on solid tumors and its unique allogeneic platform suggest a trajectory towards addressing significant unmet needs in oncology, potentially leading to breakthroughs in patient care and long-term disease control.
See full BioEclipse Therapeutics company page
